Paul Tudor Jones Kymera Therapeutics, Inc. Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 32,162 shares of KYMR stock, worth $1.26 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
32,162Holding current value
$1.26 Million% of portfolio
0.01%Shares
14 transactions
Others Institutions Holding KYMR
# of Institutions
184Shares Held
64.4MCall Options Held
50.6KPut Options Held
81.7K-
Price T Rowe Associates Inc Baltimore, MD6.65MShares$260 Million0.04% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$235 Million3.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$202 Million7.77% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$192 Million28.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.75MShares$186 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.14B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...